Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Transcarent

Claya
Graded #267

Higher grade

vs+7.599999999999994
Transcarent
Graded #445

Lower grade

The verdict

Claya takes it — 62.8/100 to 55.2/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTranscarent +3
42
45
Dose & formulationClaya +35
75
40
Clinical oversightClaya +7
82
75
Labs & monitoringTranscarent +8
53
61
FulfillmentClaya +5
67
62
Contract termsClaya +6
61
55
Claya · left barTranscarent · right bar

The numbers

MetricClayaTranscarent
WeighScore62.8/10055.2/100
GradeCC
Scorecard rank#267#445
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #267 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Transcarent

Graded #445 · C

Strengths

  • Comprehensive Weight Health pathway from lifestyle to GLP-1s to surgery
  • Care team of doctors, nurses and pharmacists supports medication use
  • Uses direct pharma contracts and a transparent PBM to cut costs
  • Integrates bariatric surgery navigation alongside medication
  • Built on 15 years of Surgery Center of Excellence experience

Where it loses points

  • Distributed only via employers and health plans, no direct cash-pay
  • GLP-1 access depends on whether the plan covers the medication
  • No public individual monthly pricing
  • Not available to consumers without an eligible employer or plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard